Identification of mouse AAV capsid-specific CD8+ T cell epitopes

Denise E. Sabatino(Children's Hospital of Philadelphia), Katherine A. High(Spark Therapeutics (United States)), Hildegund C.J. Ertl(The Wistar Institute), Daniel J. Hui(Children's Hospital of Philadelphia), Haifeng Chen(Chinese Academy of Sciences), Federico Mingozzi(Spark Therapeutics (United States)), Peter Colosi(Epigen Biosciences (United States))
Molecular Therapy
November 3, 2005
10.1016/j.ymthe.2005.09.009
Cited by 92

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Gene therapy comes of age
|Science|2018|1.4k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
|The Lancet|2016|464